CYP17 Inhibitors for Prostate Cancer Treatment – An Update

Author(s): V. M. Moreira, J. A.R. Salvador, T. S. Vasaitis, V. C.O. Njar

Journal Name: Current Medicinal Chemistry

Volume 15 , Issue 9 , 2008

Become EABM
Become Reviewer


It is almost 70 years since the discovery by Huggins et al. that androgens are essential for prostate cancer (PC) growth and progression, and there has been about 30 years experience using ketoconazole for PC theraphy. Since then we have come a long way in learning about the disease and developing new strategies to approach it, among which is cytochrome 17α-hydroxylase-C17,20-lyase (CYP17) inhibition. This review focuses on the efforts to find prospective CYP17 inhibitors, both steroidal and nonsteroidal, in the absence of a 3D structure of the enzyme. It covers almost 4 decades of literature with highlights on the most significant achievements in this area, providing insight into PC pathophysiology, management and treatment options.

Keywords: Cytochrome 17α-hydroxylase-C17,20-lyase, CYP17, androgens, Prostate Cancer, steroidal inhibitors, nonsteroidal inhibitors, ketoconazole, abiraterone

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [868 - 899]
Pages: 32
DOI: 10.2174/092986708783955428
Price: $65

Article Metrics

PDF: 6